GPT and neutropenia: The ORR, DCR and median PFS were 83.3%, 100% and 8.3 (95% CI: 3.8, 12.8) months in Cohort A, 22.2%, 55.6% and 4.2 (95% CI: 3.6, 4.8) months in Cohort B, and 41.7%, 100% and 7.2 (95% CI: 5.0, 9.4) months in Cohort C. The most common treatment-related adverse events (20% incidence and higher) included cytokine release syndrome (53.13%), leukopenia (43.75%), elevated alanine aminotransferase (43.75%), neutropenia (37.5%), constipation (31.25%), and elevated aspartate aminotransferase (28.13%).